Hematopoiesis in the embryo proceeds in a series of waves, with primitive erythroid-biased waves succeeded by definitive waves, within which the properties of hematopoietic stem cells (multilineage potential, self-renewal, and engraftability) gradually arise. Whereas selfrenewal and engraftability have previously been examined in the embryo, multipotency has not been thoroughly addressed, especially at the single-cell level or within well-defined populations. To identify when and where clonal multilineage potential arises during embryogenesis, we developed a single-cell multipotency assay. We find that, during the initiation of definitive hematopoiesis in the embryo, a defined population of multipotent, engraftable progenitors emerges that is much more abundant within the yolk sac (YS) than the aortagonad-mesonephros (AGM) or fetal liver. These experiments indicate that multipotent cells appear in concert within both the YS and AGM and strongly implicate YS-derived progenitors as contributors to definitive hematopoiesis.
INTRODUCTION
In the mammalian blood system, all mature blood lineages, including erythrocytes, platelets, and all innate and adaptive immune cells, are generated from hematopoietic stem cells (HSCs). In adults, HSCs reside almost exclusively in the bone marrow. In the embryo, however, hematopoiesis is characterized by distinct yet overlapping waves of blood development, appearing in multiple sites, with primitive erythroid-biased waves succeeded by definitive waves with increasing lineage potential and functionality. The functional properties that define adult HSCs do not appear at once during development but emerge gradually over the course of several days.
In the mouse embryo, the first blood-forming cells appear approximately 7.5 days into gestation (embryonic day [E] 7.5) within the blood islands that line the extraembryonic yolk sac (YS) (Moore and Metcalf, 1970) . These ''primitive'' blood-forming cells appear to be lineagerestricted, form primarily large nucleated erythrocytes, and express embryonic globins (Palis et al., 1999) . They also lack the ability to engraft when transplanted intravenously into lethally irradiated adult mice, a hallmark property of fully functional adult bone marrow HSCs (Müller et al., 1994) . After the establishment of a circulatory system at e8.5, ''definitive'' erythromyeloid progenitors appear within the YS (Palis et al., 1999) , the placenta (PL) (Alvarez-Silva et al., 2003) , and the embryo proper (EP).
The earliest intraembryonic hematopoietic progenitors are found within the para-aortic splanchnopleura (p-Sp), which develops into the aorta-gonad-mesonephros (AGM) that contains the dorsal aorta (Cumano et al., 1996; Godin et al., 1993 Godin et al., , 1995 Medvinsky et al., 1993) . Hematopoietic progenitors with the ability to self-renew appear within the YS and AGM at e9.0 and appear within the fetal liver (FL) a day or two later (Yoder and Hiatt, 1997) . e9.5 YS cells lack the ability to home to the bone marrow when transplanted into adult mice, but their long-term self-renewal activity can be revealed in vivo by transplantation into the liver or facial vein of sublethally irradiated newborn mice (Yoder and Hiatt, 1997; Yoder et al., 1997a Yoder et al., , 1997b or alternatively by first coculturing with reaggregated AGM tissue (Taoudi et al., 2008) or on the OP9 bone marrow stromal line (Rybtsov et al., 2011) , indicating that progenitors residing within the YS can mature into functional HSC. These embryonic progenitors were thought to be precursors to HSCs, or ''pre-HSCs,'' and whereas not precisely defined, pre-HSCs expressed markers associated with endothelial (VE-cadherin) and hematopoietic (CD41 then CD45) cells (Rybtsov et al., 2011) . At e10.5, fully functional HSCs have been isolated from the dorsal aorta of the AGM region (Müller et al., 1994) , the extraembryonic YS, PL (Gekas et al., 2005) , and from the vitelline and umbilical vessels (de Bruijn et al., 2000) . At e11.5, HSCs are also found within the FL, which then becomes the predominant site of hematopoiesis until the formation (B) Strategy for clonal assay. ODT stroma is plated the day prior to cell sorting (day À1). At day 0, cells are clone sorted directly onto ODT stroma and cytokines are added (SCF, TPO, EPO, Flt3L, . At day 3, hematopoietic colonies are counted. At day 5, cells are fed and Flt3L, IL-7, IL-15, and DOX (1 mg/ml) are added. At day 9 or 10, colonies are harvested and analyzed by FACS. (C) Representative hematopoietic output at day 10 of culture of unsorted e12.5 FL. Representative examples of multipotent output from single-cell cultures can be found in Figure S1 . 
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Mouse Embryonic Multipotent Hematopoietic Cells of a bone-marrow cavity several days later (Gekas et al., 2005; Müller et al., 1994) . Thus, the maturation of bloodforming cells takes place in discrete steps and likely at several different sites. A fundamental unresolved question is whether definitive hematopoietic cells derive directly from the primitive precursors that first appear in the YS blood islands (Moore and Metcalf, 1970) or instead emerge separately from a hematoendothelial precursor in the dorsal aorta called hemogenic endothelium (Dzierzak and Medvinsky, 1995; Nishikawa et al., 1998) . A large body of evidence supports the de novo generation of HSCs within the dorsal aorta, including ex vivo tissue explants of the dorsal aorta prior to circulation (Cumano et al., 1996 (Cumano et al., , 2001 Medvinsky and Dzierzak, 1996) . Also, time-lapse imaging of AGM sections in culture reveals the emergence of hematopoietic clusters from within the luminal wall of the dorsal aorta in mice, which express several HSC markers, such as KIT, SCA-1, and CD41 (Boisset et al., 2010) . Definitive hematopoietic progenitors also exist within the YS (Huang and Auerbach, 1993; Kumaravelu et al., 2002) . However, early studies could not exclude the possibility that such progenitors originated elsewhere and then migrated to the YS. Evidence supporting a distinct YS origin of definitive hematopoiesis comes from lineage-tracing experiments that used a Runx1 Cre-estrogen receptor (ER) reporter to exclusively label YS-derived hematopoietic cells; subsequent analysis of these mice revealed labeling of adult HSCs (Samokhvalov et al., 2007) . Similarly, inducible rescue of Runx1 expression in Runx1 knockout embryos demonstrated that definitive hematopoiesis could only be rescued at the developmental stages when Runx1 expression was restricted to the YS (Tanaka et al., 2012) . In Ncx1 À/À embryos, which lack a heartbeat and thus circulation, all hematopoietic cells are found within the YS and PL prior to embryonic lethality at e10.5 Rhodes et al., 2008) . Additionally, transplantation of YS cells from e8 to e9 allogeneic donors into the YS cavities of e8 to e9 hosts in utero led to YS blood-island engraftment and, when analyzed several months after birth, gave rise to donor-derived spleen colony-forming myeloerythroid cells and thymic and peripheral T cells (Weissman et al., 1977 (Weissman et al., , 1978 . Therefore, maturation of early YS stem/ progenitors to adult HSC was demonstrated, but the cellular identity of HSC precursors, their sites of maturation, and the molecular mechanisms involved remain a mystery.
Identification of the key populations that give rise to each wave of embryonic hematopoiesis may provide critical insights into the relationship between primitive and definitive hematopoiesis. However, the surface markers used to isolate adult HSCs and downstream stages have proven unreliable for identifying the equivalent embryonic populations (Cumano and Godin, 2007) . As a result, the cells that initiate each hematopoietic wave remain poorly defined. Multipotency in hematopoiesis refers to the ability of a progenitor to give rise to all blood lineages: myeloid cells including erythrocytes, platelets, monocytes, tissue macrophages, and granulocytes, as well as lymphocyte lineages including T, B, natural killer (NK), and dendritic cells. Multipotency also distinguishes definitive hematopoiesis from more primitive cells with limited lineage potential. Conclusive evidence of multipotency requires a single-cell assay to prevent the false positives that may occur when mixtures of lineage-committed progenitors collectively produce all lineages. In the embryo, multipotency was first observed within the AA4.1 + p-Sp population at e9.5 (Godin et al., 1995 (Huang and Auerbach, 1993) . Thus, whereas much is known about the timing of appearance of progenitor potentials within the early embryo, the clonal identities of the cells with multipotent potentials are less clear. Therefore, we sought to define the earliest clonally multipotent cells and to determine their distribution within the sites of early hematopoiesis.
RESULTS

Development of an In Vitro Clonal Multilineage Assay
In order to identify clonally multipotent populations throughout embryonic development, we developed a single-cell multipotency assay (Figure 1 ). The bonemarrow-derived OP9 stromal line can be used to generate most hematopoietic lineages in culture, with the notable exception of T lymphocytes (Kodama et al., 1994) . Alternatively, a modified OP9 stromal line that expresses Dll1 (OP9-DL1) can promote T lineage development but inhibits B cell development (Schmitt and Zú ñiga-Pflücker, 2002 
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Mouse Embryonic Multipotent Hematopoietic Cells sought a method to generate both B cells and T cells from a single cell within a single well. We previously published an assay whereby common lymphocyte progenitors could be cultured and expanded on OP9 stroma without committing to either the B or T cell lineages (Karsunky et al., 2008) . We therefore generated an OP9 stromal line with an inducible Dll1 expression cassette ( Figure 1A In our assay conditions, hematopoietic stem and progenitor cells give rise to distinct colonies by day 3, and thus we could also use this assay to identify markers for these cells. We initially screened eight markers (KIT, CD43, CD34, CD41, SCA-1, CD45, AA4.1, and SLAMF1) from YS, AGM, and FL tissues from e9.5 to e12.5 to identify which markers could consistently enrich or deplete for colony-forming activity ( Figure S2 ). For most markers, colony-forming activity was found in both the positive and negative fractions. For example, whereas the hematopoietic marker CD41 could enrich hematopoietic colonyforming ability at e9.5, it became downregulated at later time points, resulting in colony-forming activity within the CD41 À fraction ( Figure S2A ). However, two markers, KIT and CD43, nearly uniformly marked all colony-forming cells in all tissues from e9.5 to e12.5.
Emergence of Multipotent KLS Cells during Embryogenesis
Based on our initial screen, we restricted the search for multipotent cells to subpopulations within the KIT S3 ). In the adult, all multipotent stem and progenitors are found in the KLS fraction. We identified a similar population that is KIT + CD43 + and SCA-1 + , which appears in e9.5 YS and AGM and e11.5 FL ( Figure 2 ). This population is highly enriched for colonyforming activity (between 35% and 50% of plated cells gave rise to colonies) and, as a population, gives rise to all lineages in vitro (data not shown). We refer to this embryonic population as KLS (KIT + Lin À SCA-1 + ) to reflect its similarity to the analogous KLS population in adult BM, although embryonic KLS cells also are defined by expression of CD43, and the only required lineage marker for negative gating is the red-blood-cell marker TER119 ( Figure S3A ).
In adult BM, myeloid progenitors are found within the KIT + SCA-1 À (MYP) fraction, which contains common myeloid progenitors (CMP), granulocyte-monocyte progenitors (GMP), and megakaryocyte-erythrocyte progenitors (MEP) (Akashi et al., 2000) . In the embryo, we identified a similar MYP population, from which emerged CMP and then MEP and GMP, both by surface phenotype and in vitro lineage potential ( Figure S3B ; data not shown).
CD11A Expression Divides Embryonic KLS into Two Distinct Fractions
The surface markers SLAMF1, FLK2, and CD34 are known to subdivide adult KLS into HSCs and downstream multipotent progenitors ( Figure 1D ). We examined these markers in embryonic KLS and found that their expression levels varied from time point to time point and from tissue to tissue, making the use of these markers unreliable to subdivide embryonic KLS prior to e11.5 ( Figure S4 ). However, we did find that the KLS population could be consistently subdivided based on expression of CD11A ( Figure 3A ). CD11A (Itgal) is a component of the leukocyte adhesion Figure 3A ). We also examined the expression of several other markers including the endothelial-associated markers TIE2 and endoglin and the hematopoietic markers CD45 and MAC-1 ( Figure S5 ). Whereas the expression patterns of these markers were less consistent than CD11A and VE-cadherin across all tissues and time points, in general we found that endothelial markers were more highly expressed at earlier time points and on CD11A À KLS cells, whereas hematopoietic markers were more highly expressed at later time points and on CD11A + KLS cells.
We next tested CD11A À and CD11A + KLS cells for clonal multilineage potential ( Figures 3B and 3C ). In adult BM, the KLS population contains all multipotent cells ( Figures  1D-1F 
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Mouse Embryonic Multipotent Hematopoietic Cells population, we found bipotent MegE/GM and GM/L colonies but never all three branches at once, regardless of time point or tissue ( Figure 3C ). Thus, the CD11A À KLS cells population contains all the multipotent cells from e9.5 to e11.5 and appears in both extra-and intraembryonic regions around e9.5.
YS Contains the Most Multipotent Cells from E9.5 to E11.5 Our assay also allowed us to estimate the numbers of multipotent progenitors in each tissue from e9.5 to e11.5, based on colony-forming activity ( Figure 4A ). We found that, from e8.5 to e10.5, the YS contained the majority of Figure 4B ) and the frequency of multipotent cells within each tissue ( Figure 3B ), we could estimate the absolute number of multipotent cells ( Figure 4E ). We found that e10.5 YS contains the most multipotent cells of all tissues and time points examined, and at e11.5, the YS still contained more multipotent cells than AGM or FL. Taken together, our examination of the absolute number of CD11A À KLS and multipotent cells suggests that the YS is a major source of multipotent cells at the stages when fully functional HSCs first appear in embryonic development.
EPCR Marks a Subset of CD11A À KLS and Can Partially Enrich for Multipotency
The protein C receptor EPCR (CD201; Procr) has previously been reported to be expressed in adult HSCs, as well as embryonic FL e12.5 HSCs (Balazs et al., 2006; Iwasaki et al., 2010) . We found that EPCR is expressed on a subset of KLS cells as early as e9.5 and remains expressed throughout gestation ( Figure 5A ). EPCR expression correlates with high VE-CAD expression and lower CD11A expression. Using the clonal multipotency assay, we observed multipotent colony formation from both EPCR + and EPCR À subsets of CD11A À KLS cells, though multipotency appeared greater in the EPCR + subfraction overall ( Figures 5B, 5C , and S1). We also identified CD11A À and CD11A + KLS cells in the placenta ( Figure S6 ), a region known to be a niche for hematopoietic stem cells (Gekas et al., 2005; Ottersbach and Dzierzak, 2005) , and included placental populations in the analysis. Although we did not observe multipotency in e10.5 PL CD11A À KLS, we did find it within the EPCR + CD11A À KLS at e11.5 in the PL. Taken together, our data suggest that EPCR can partially enrich for multipotent cells, though not all multipotent cells are EPCR + .
Lineage-Tracing KLS Cells In Vivo
To better understand the lineage relationship between CD11A À and CD11A + KLS cells, we examined two lineage-tracing reporter mouse strains ( Figure S7 ). CD11A
À KLS cells generally express higher levels of TIE2 than CD11a + KLS cells ( Figure S5A ); thus, we crossed Tie2
Cre mice (Kisanuki et al., 2001 ) to the mT/mG reporter strain (Muzumdar et al., 2007) , which permanently switches from Tomato to GFP fluorescence in any cell that expresses Cre ( Figure S7A ). In the Tie2 cre 3 mT/mG embryos, we found that all KLS cells were GFP + and thus derived from TIE2-expressing precursors ( Figure S7B Figure S1 .
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Multipotency Moves into the CD11A
+ KLS Subfraction at E12.5 By e12.5, the FL is by far the dominant site of hematopoiesis and is known to produce fully functional HSCs by transplantation (Morrison et al., 1995) . When we examined e12.5 FL KLS, nearly all (95%) of KLS cells were CD11A + ( Figure 6A ). When we examined both CD11A À and CD11A + KLS cells, calculated as in Figure 4E . compare engraftment and lineage potential between these two populations in the same recipient animals. We also cotransplanted 100 adult BM KLS cells as an internal control. Cells were sorted from e11.5 YS, AGM, FL, and the vitelline/ umbilical (VU) region, which is also known to contain preHSCs and HSCs at this time point (de Bruijn et al., 2000; Gordon-Keylock et al., 2013) . Because e11.5 hematopoietic progenitors have poor engraftment potential when transplanted into adult animals, we instead transplanted intravenously into irradiated newborn nonobese diabetic-severe combined immunodeficiency-gc À/À (NSG) recipients. When we examined donor chimerism in the blood of recipient mice, we found substantially more donor cells derived from CD11A
À KLS cells than from CD11A + KLS cells in all recipient mice ( Figures 7A and 7B) , despite transplanting nearly a 5-fold excess of CD11A + KLS cells ( Figure 7A ).
Whereas the level of donor chimerism varied considerably from recipient to recipient, in every case, the contribution of CD11A + KLS cells was either minor or absent, indicating these cells are much less effective at engraftment than CD11A À KLS cells. We also examined the lineage distribution of donor-derived cells ( Figures 7C and 7D ). Whereas all recipients contained donor-derived lymphocytes, only two had significant donor myeloid cells (FL #1 and VU #1). We focused on the recipient ''FL #1'' and found that CD11A À KLS cells produced robust B cells, T cells, NK cells, granulocytes, and macrophages ( Figure 7C ). Conversely, CD11A + KLS cells produced only a modest number of B cells and T cells, which faded over time ( Figures  7C and 7D ). Because erythrocytes and platelets do not express CD45, a marker we used to distinguish donor and recipient cells, we were unable to determine whether CD11A À KLS could produce these lineages, but all other major hematopoietic lineages were detectable and robust at 15 weeks posttransplantation, suggesting that CD11A À KLS cells are multipotent both in vivo and in vitro.
DISCUSSION
The essential properties of adult HSCs include the capacity to maintain themselves indefinitely (self-renewal), the ability to differentiate into all hematopoietic lineages (multipotency), and the ability to circulate from the blood to niches in the bone marrow (engraftability). It remains unclear whether HSCs develop from hematopoieticcommitted precursor cells that contain some, but not all, three HSC properties or instead whether HSCs arise de novo from a hematoendothelial precursor. Earlier studies had suggested that hematopoietic precursors to HSCs (i.e., pre-HSCs) exist within the fetus and that these progenitors lacked the ability to home to the bone marrow but could be matured in vitro into bona fide, bonemarrow-homing HSCs (Gordon- Keylock et al., 2013; Rybtsov et al., 2011) . We have adopted an alternative strategy to identify such precursors to HSCs. We hypothesize that HSC precursors have the property of multipotency, and we developed a single-cell assay to reductively identify, quantify, and characterize multipotent cells in the early embryo.
Our data indicate that multipotent cells are predominantly localized to the YS during the stages when definitive, selfrenewing HSC precursors are thought to arise (e9.5-e10.5). It remains unclear whether HSCs arise from both intraembryonic (AGM and FL) and extraembryonic (YS and PL) tissues or if they emerge from a single site and migrate elsewhere. Our absolute cell number data indicate that the YS contains by far the most multipotent cells during the critical stages during which HSCs arise. Pre-HSCs or HSCs may also emerge de novo from hemogenic endothelium in the AGM, but our data suggest that the AGM region by itself does not produce enough multipotent cells to account for all the multipotent cells in the embryo and that likely the vast majority come from the extraembryonic YS. This is consistent with previous work estimating the absolute number of HSCs during gestation, suggesting that both the YS and AGM may contribute to the FL HSC pool (Kumaravelu et al., 2002) . Additionally, our previous work showing direct orthotopic synchronic transplantation of e8 to e9 YS cells showed that YS-derived cells can indeed contribute to complete and lifelong adult hematopoiesis (Weissman et al., 1978) . Many of the surface markers we used to define embryonic hematopoietic populations have functional roles in cell adhesion and trafficking. VE-cadherin is an endothelial adhesion molecule involved in facilitating the adherens junctions between endothelial cells (Harris and Nelson, 2010) . CD11A is part of a leukocyte adhesion complex (LFA-1) known to play a role in leukocyte extravasation from the vasculature by binding to ICAMs on endothelial cells (Hogg et al., 2011) . In a related study, we show that CD11A is upregulated as HSCs lose self-renewal potential and may be involved in HSC mobilization out of the bone marrow (J.W.F., M.A.I., Nathaniel B. Fernhoff, J.S., and I.L.W., unpublished data). In this study, we show that CD11A upregulation is also associated with the loss of multilineage potential and marks a subset of lineagecommitted progenitors that are downstream of embryonic multipotent cells. These changes in adhesion molecule expression may play an important role in the migration of progenitors from their tissues of origin (YS, PL, and AGM) to secondary sites of hematopoiesis (FL and BM). For example, the downregulation of VE-cadherin may allow cells to detach from the endothelium and enter circulation, whereas the upregulation of CD11A may allow cells to exit circulation and seed new sites.
In this study, we created an assay to look for clonal multilineage potential and used it to identify emerging multipotent hematopoietic progenitors within the embryo. Other markers we focused on were also critical for distinguishing multipotent cells from downstream progenitors. Due to space limitations, we include an in-depth technical discussion of these markers and their use in the Supplemental Information. Our data suggest that a multipotent, selfrenewing hematopoietic wave arises in the YS blood islands and appears simultaneously in multiple sites at e9.5. We confirmed the multipotency of this population in vivo. We hypothesize that this population represents a critical intermediate in the origins of definitive hematopoiesis, and armed with a panel of markers that can identify these cells with high resolution, we can now begin to dissect the critical steps in the emergence of and maturation of the first HSCs in embryonic development.
EXPERIMENTAL PROCEDURES
Antibodies
A detailed list of all antibodies used in this study is shown in Table S1 .
Clonal Multipotency Assay
ODT stroma was cultured as described (Vodyanik and Slukvin, 2007) . Briefly, ODT was plated onto gelatin-coated dishes and cultured in the presence of OP9 media (aMEM [made from powder, Invitrogen catalog No. 12000-022] in 20% serum . ODT was passaged around 1:10 every 5 days. OP9 cells differentiate rapidly to adipocytes when confluent, so great care was taken to avoid confluence. For clonal assays, ODT was plated 
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Mouse Embryonic Multipotent Hematopoietic Cells the day prior to use onto gelatin-coated 96-well plates (Falcon 3072), around 1,000-2,000 cells per well, in OP9 media. The day of use, the media was replaced with 100 ml of differentiation media (described in Vodyanik and Slukvin, 2007) , aMEM, 10% serum, 100 mM monothioglycerol (catalog No. M6145; Sigma), 50 mg/ml ascorbic acid (catalog No. A-0278; Sigma), 100 U/ml penicillin/ 100 mg/ml streptomycin (catalog No. 15140; Invitrogen), and 13 GlutaMAX (catalog No. 35050; Invitrogen) and the cytokines SCF (rmSCF; Peprotech 250-03; 10 ng/ml), TPO (rmTPO; Peprotech 315-14; 10 ng/ml), EPO (rhEPO; Invitrogen PHC2054; 0.5 U/ml), Flt3L (mFlt3L; Peprotech 250-31L; 10 ng/ml), IL-7 (mIL-7; Peprotech 217-17; 10 ng/ml), and IL-15 (IL15/IL15R complex; Ebioscience 14-8152; 5 ng/ml) were added. Colonies were visibly confirmed at 3 days after plating. Around 4 to 5 days after plating, wells with colonies were fed by adding 100 ml of differentiation media with IL-7 (10 ng/ml), IL-15 (5 ng/ml), and DOX (1 mg/ml). All wells with colonies at day 3 were harvested, stained, and analyzed on a BDFortessa FACS analyzer with a high-throughput sampler on FACS Diva software (BD Biosciences). 
Mouse Embryo Harvest and Cell Sorting
All animal procedures were approved by the International Animal Care and Use Committee and the Stanford Administrative Panel on Laboratory Animal Care. Matings of C57B6 mice were established and plugs checked in the mornings. Pregnant females were harvested in the mornings and embryos dissected immediately. Vitelline and umbilical vessels were typically harvested with the yolk sac, except where indicated. For the AGM harvest, the head, tails, feet, and fetal liver/heart were removed, and the remaining tissue was listed as AGM. Tissues were dissociated in 10 mg/ml Collagenase Type IV (Invitrogen 17104-019) for approximately 30 min to 1 hr, pipetted up and down and filtered in 70 micron mesh. Tissues were typically stained for 15 min on ice in staining media. See Table S1 for antibodies used. Cells were analyzed and/or sorted on a BD FACSAria using FACS Diva software. For clone sorting, a 100-micron nozzle was used, and cells were single sorted on ''single cell'' mode directly onto 96-well plates with ODT stroma. The authors highly recommend doing a single sort (as opposed to a double sort) due to substantial loss of rare cells upon the second sort. We also recommend avoiding the use of ACK lysis buffer prior to Ab staining, as it dramatically reduces the VE-cadherin signal.
In Vivo Transplantation and Analysis 
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